{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:09:49Z","timestamp":1791853789633,"version":"4.3.4"},"reference-count":40,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Plaque psoriasis is a chronic inflammatory disorder affecting the skin and impacting quality of life. Tildrakizumab (TIL) is an IL\u201023 inhibitor licensed for moderate\u2010to\u2010severe plaque psoriasis. Regulatory approval of medicinal products is based on safety and efficacy data from randomized controlled trials (RCTs) which impose stringent selection criteria. Long\u2010term non\u2010interventional studies (NIS) are needed to establish effectiveness and safety in daily practice bridging the gap between RCTs and the real\u2010world setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This analysis of the NIS TILOT seeks to evaluate effectiveness and safety of TIL in patients with moderate\u2010to\u2010severe plaque psoriasis in a real\u2010world setting. Secondary objectives include the assessment of the Dermatology Life Quality Index (DLQI), treatment satisfaction and course of scalp and nail disease using Physician Global Assessment (PGA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Interim analysis at 52\u2009weeks (W) of the ongoing non\u2010interventional, prospective, long\u2010term multicentre study TILOT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The effectiveness analysis included 412 patients. The mean [standard deviation, SD] Psoriasis Area and Severity Index (PASI) score was 16.0 [9.1] at baseline improving by 82.4% (95% confidence interval [CI], 78.9\u201386.0) to 2.1 [2.9] at W52. The proportion of patients achieving PASI scores of &lt;3 and &lt;5 increased over time peaking at 74.6% (95% CI, 69.3\u201379.4) and 88.4% (95% CI, 84.3\u201391.8) at W52. Scalp\u2010PGA and nail\u2010PGA improved by 79.8% (95% CI, 75.6\u201384.0) and 72.7% (95% CI, 63.9\u201381.6), respectively. DLQI of 0\/1 was achieved by 48.2% (95% CI, 42.3\u201354.2). Nine out of 10 physicians and patients expressed a high level of treatment satisfaction. No new safety signals were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This prospective cohort study demonstrates a high degree of effectiveness and a reassuring safety profile of TIL in a real\u2010world setting over 52\u2009weeks. Patients with scalp and nail involvement or pruritus showed marked improvements.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.18572","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T16:09:12Z","timestamp":1662480552000},"page":"85-92","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Real\u2010world effectiveness and safety of tildrakizumab in long\u2010term treatment of plaque psoriasis: Results from the non\u2010interventional, prospective, multicentre study <scp>TILOT<\/scp>"],"prefix":"10.1111","volume":"37","author":[{"given":"Athanasios","family":"Tsianakas","sequence":"first","affiliation":[{"name":"Fachklinik Bad Bentheim  Bad Bentheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Schwichtenberg","sequence":"additional","affiliation":[{"name":"Derma Nord Hautarztpraxen  Bremen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pierchalla","sequence":"additional","affiliation":[{"name":"Haut\u00e4rzte in Recklinghausen  Recklinghausen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Hinz","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr Hautgesundheit  Neuwied Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Diemert","sequence":"additional","affiliation":[{"name":"Almirall Hermal GmbH  Reinbek Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Korge","sequence":"additional","affiliation":[{"name":"Hautarztpraxis D\u00fcren  D\u00fcren Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15610"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743180"},{"key":"e_1_2_9_4_1","first-page":"504","article-title":"The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives","volume":"9","author":"Feldman SR","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.10.026"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1729335"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-35"},{"key":"e_1_2_9_8_1","first-page":"199","article-title":"Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate\u2010to\u2010severe psoriasis using structural equation modeling","volume":"7","author":"Lewis\u2010Beck C","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04000.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2014.996514"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31279-5"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19866"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0723"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.11.040"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08732.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.2768"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.0183"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15878"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2642"},{"key":"e_1_2_9_20_1","unstructured":"European Medicines Agency.Ilumetri.2018.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ilumetri. Accessed 16 Dec 2021."},{"key":"e_1_2_9_21_1","unstructured":"World Bank Group \u2013 International Development Poverty & Sustainability.World Bank.https:\/\/www.worldbank.org\/en\/home. Accessed 23 Feb 2022."},{"key":"e_1_2_9_22_1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/ddg.12233","article-title":"German psoriasis registry PsoBest: objectives, methodology and baseline data","volume":"12","author":"Augustin M","year":"2014","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1747590"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1640348"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03364.x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000246274"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000519924"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16724"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16128"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00556-2"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v101.283"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16715"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16511"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406223211046685"},{"key":"e_1_2_9_35_1","first-page":"406","article-title":"Real\u2010world effectiveness and safety of Guselkumab for the treatment of psoriasis: a 6\u2010month prospective study in a series of psoriatic patients","volume":"25","author":"Malara G","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1800577"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2081655"},{"key":"e_1_2_9_38_1","first-page":"e355","article-title":"Tildrakizumab: short\u2010term efficacy and safety in real clinical practice","volume":"61","author":"Gal\u00e1n\u2010Gutierrez M","year":"2021","journal-title":"Int J Dermatol"},{"key":"e_1_2_9_39_1","first-page":"2021\u20102\u20106","article-title":"Treatment of moderate\u2010to\u2010severe plaque psoriasis with tildrakizumab in the real\u2010life setting","volume":"10","author":"Burlando M","year":"2021","journal-title":"Drugs Context"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00622-7"},{"key":"e_1_2_9_41_1","first-page":"309","article-title":"Quality of life in patients with scalp psoriasis","volume":"150","author":"Zampieron A","year":"2015","journal-title":"G Ital Dermatol Venereol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18572","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.18572","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T07:30:25Z","timestamp":1692689425000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.18572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1111\/jdv.18572"],"URL":"https:\/\/doi.org\/10.1111\/jdv.18572","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]},"assertion":[{"value":"2022-04-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}